US Stock MarketDetailed Quotes

NX Quanex Building Products

Watchlist

19.710
-0.060-0.30%

Close Mar 26 16:00 ET

19.710
0.0000.00%

Post 16:05 ET

930.91MMarket Cap50.54P/E (TTM)

Quanex Building Products Stock Forum

Moomoo AI

Mar 25, 2024 20:54

The company's low P/E is due to its outlook for shrinking earnings. Investors believe the potential for earnings improvement doesn't justify a higher P/E, limiting the chances of a strong share price rise soon.

Investors Don't See Light At End Of Quanex Building Products Corporation's (NYSE:NX) Tunnel

Moomoo AI

Feb 13, 2024 23:11

Quanex Building Products is undervalued, presenting a good opportunity to increase holdings. The company's future outlook isn't fully reflected in the current share price, making it a good time to invest.

At US$33.80, Is Quanex Building Products Corporation (NYSE:NX) Worth Looking At Closely?

Moomoo AI

Jan 4, 2024 19:36

The large scale share sell-off from the Independent Lead Director around current prices raises concern. Lack of recent insider purchases despite significant ownership increases caution towards the company.

Trade Alert: Independent Lead Director Of Quanex Building Products Susan Davis Has Sold Stock

Moomoo Breakfast US

Sep 2, 2022 21:01

Columns Today's Pre-Market Stock Movers: AVGO, RKLB, LULU, XOM and More

Gapping up
In reaction to earnings/guidance:
• $HashiCorp (HCP.US)$ +16.8%, $Lululemon Athletica (LULU.US)$ +9.7%, $PagerDuty (PD.US)$ +5%, $nCino (NCNO.US)$ +3.8% (also Bank Operating System selected by Rabobank Australia and New Zealand), $Broadcom (AVGO.US)$ +2.1%
Other news:
• $Ooma (OOMA.US)$ +3.5% (acquires Junction Networks also reports earnings)
• $Momentus (MNTS.US)$ +3.5% (files for $200 mln mixed securities shelf offering)
• $Humacyte (HUMA.US)$ +2.9% (fi...

Moomoo Breakfast US

Jun 3, 2022 20:29

Columns Today's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more

Gainers:
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...